Oslo University Hospital
oslo-universitetssykehus.noLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
822
Active
192
Phase 3
41
Total enrollment
995,997
Pipeline matrix
Showing 40 of 67 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Methotrexate | — | — | — | — | 2 | ||
| Ipilimumab | — | — | — | — | 2 | ||
| Nepafenac Ophthalmic | — | — | — | — | — | 2 | |
| Dexamethasone Ophthalmic | — | — | — | — | — | 2 | |
| Betablocker | — | — | — | — | — | 1 | |
| TNF Inhibitor | — | — | — | — | — | 1 | |
| Dapagliflozin 10mg Tab | — | — | — | — | — | 1 | |
| Metoprolol | — | — | — | — | 2 | ||
| Acetylsalicylic acid | — | — | — | — | — | 2 | |
| 5-FU | — | — | — | — | 2 | ||
| Buscopan 20 MG/ML Injectable Solution | — | — | — | — | — | 1 | |
| Sodium bicarbonate | — | — | — | — | — | 1 | |
| Nacl 0.9% | — | — | — | — | — | 1 | |
| Flecainide | — | — | — | — | — | 1 | |
| CGRP mAbs and onabotulinumtoxin A | — | — | — | — | — | 1 | |
| CGRP mAbs and placebo | — | — | — | — | — | 1 | |
| Dapagliflozin 10 mg | — | — | — | — | — | 1 | |
| Oxaliplatine | — | — | — | — | — | 1 | |
| Irinotecan | — | — | — | — | — | 1 | |
| Early treatment of relapse with carfilzomib, dexamethasone, daratumumab | — | — | — | — | — | 1 | |
| Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | 3 | ||
| Floxuridine | — | — | — | — | — | 2 | |
| Apixaban | — | — | — | — | 2 | ||
| Dexamethasone | — | — | — | — | 2 | ||
| Nivolumab | — | — | — | — | — | 3 | |
| Atezolizumab | — | — | — | — | — | 3 | |
| Alectinib | — | — | — | — | — | 1 | |
| Cetuximab | — | — | — | — | — | 1 | |
| Crizotinib | — | — | — | — | — | 1 | |
| Dasatinib | — | — | — | — | — | 1 | |
| Everolimus | — | — | — | — | — | 1 | |
| Encorafenib | — | — | — | — | — | 1 | |
| Gemcitabine | — | — | — | — | — | 1 | |
| Idelalisib | — | — | — | — | — | 1 | |
| Larotrectinib | — | — | — | — | — | 1 | |
| Palbociclib | — | — | — | — | — | 1 | |
| Panobinostat | — | — | — | — | — | 1 | |
| Petrozumab | — | — | — | — | — | 1 | |
| Trastuzumab | — | — | — | — | — | 1 |
27 more active programs hidden
Next readouts
- 2018-12
- 2021-11-01
- 2021-12-31
- 2022-02-01
- 2022-10-31
- 2022-12-22
- 2024-06
- 2025-01-31
- 2025-04-04
- 2025-05
Top conditions
- Cancer17
- Prostate Cancer15
- Quality of Life14
- Pain13
- Colorectal Cancer10
- Coronary Artery Disease9
- Breast Cancer8
- Atrial Fibrillation8
Frequently asked questions about Oslo University Hospital
- How many clinical trials does Oslo University Hospital have on ClinicalTrials.gov?
- Oslo University Hospital is listed as the lead sponsor on 822 clinical trials in ClinicalTrials.gov, 192 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Oslo University Hospital's trials are in Phase 3?
- 41 of Oslo University Hospital's trials are in Phase 3, spread across 67 active drug programs.
- What therapeutic areas does Oslo University Hospital focus on?
- Oslo University Hospital's most-studied conditions on ClinicalTrials.gov are Cancer, Prostate Cancer, Quality of Life, Pain, Colorectal Cancer.
- When are Oslo University Hospital's next clinical trial readouts?
- Oslo University Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Nesiritide in Hypertension”, expected around 2018-12.